Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model.

Gaines AR, Lee-Stroka H, Byrne K, Scott DE, Uhl L, Lazarus E, Stroncek DF.

Transfusion. 2009 Jun;49(6):1050-8. doi: 10.1111/j.1537-2995.2008.02083.x. Epub 2009 Feb 9.

3.

Intravenous Rh immune globulin for treating immune thrombocytopenic purpura.

Sandler SG.

Curr Opin Hematol. 2001 Nov;8(6):417-20. Review. Erratum in: Curr Opin Hematol 2002 Mar;9(2):179.

PMID:
11604585
4.

Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura.

Kees-Folts D, Abt AB, Domen RE, Freiberg AS.

Pediatr Nephrol. 2002 Feb;17(2):91-6. Review.

PMID:
11875670
5.

Treatment of acute immune thrombocytopenic purpura.

Tarantino MD, Goldsmith G.

Semin Hematol. 1998 Jan;35(1 Suppl 1):28-35. Review.

PMID:
9523747
6.

Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review.

Ainsworth CD, Crowther MA, Treleaven D, Evanovitch D, Webert KE, Blajchman MA.

Transfus Med Rev. 2009 Apr;23(2):155-9. doi: 10.1016/j.tmrv.2008.12.005. Review.

PMID:
19304116
7.

Pathogenesis and mechanisms of antibody-mediated hemolysis.

Flegel WA.

Transfusion. 2015 Jul;55 Suppl 2:S47-58. doi: 10.1111/trf.13147. Review.

8.

Intravenous anti-D immunoglobulin in the management of immune thrombocytopenic purpura.

Smith N.

Curr Opin Hematol. 1996 Nov;3(6):498-503. Review.

PMID:
9372124
9.

RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

Despotovic JM, Lambert MP, Herman JH, Gernsheimer TB, McCrae KR, Tarantino MD, Bussel JB.

Transfusion. 2012 May;52(5):1126-36; quiz 1125. doi: 10.1111/j.1537-2995.2011.03384.x. Epub 2011 Oct 7. Review.

10.

Immune hemolysis-serological and clinical aspects.

Pruss A, Salama A, Ahrens N, Hansen A, Kiesewetter H, Koscielny J, Dörner T.

Clin Exp Med. 2003 Sep;3(2):55-64. Review.

PMID:
14598182
11.

Passenger lymphocyte syndrome with or without immune hemolytic anemia in all Rh-positive recipients of lungs from rhesus alloimmunized donors: three new cases and a review of the literature.

Cserti-Gazdewich CM, Waddell TK, Singer LG, Chaparro C, Pendergrast JM, Hawes J, denHollander N, Tinckam K, Keshavjee S.

Transfus Med Rev. 2009 Apr;23(2):134-45. doi: 10.1016/j.tmrv.2008.12.003. Review.

PMID:
19304114
12.

Use of intravenous immune globulin therapy: an overview.

Wordell CJ.

DICP. 1991 Jul-Aug;25(7-8):805-17. Review.

PMID:
1949941
13.

Anti-D: mechanisms of action.

Ware RE, Zimmerman SA.

Semin Hematol. 1998 Jan;35(1 Suppl 1):14-22. Review.

PMID:
9523745
14.

Treating immune thrombocytopenic purpura and preventing Rh alloimmunization using intravenous rho (D) immune globulin.

Sandler SG.

Transfus Med Rev. 2001 Jan;15(1):67-76. Review. No abstract available.

PMID:
11149979
15.

Rh(O)D immune globulin products for prevention of alloimmunization during pregnancy.

Aitken SL, Tichy EM.

Am J Health Syst Pharm. 2015 Feb 15;72(4):267-76. doi: 10.2146/ajhp140288. Review.

PMID:
25631833
16.

Safety profile of WinRho anti-D.

Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M.

Semin Hematol. 1998 Jan;35(1 Suppl 1):9-13. Review.

PMID:
9523744
17.

[Idiopathic thrombocytopenic purpura in children].

Gebauer E, Vijatov G.

Med Pregl. 1998 Mar-Apr;51(3-4):127-34. Review. Croatian.

PMID:
9611955
18.

Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.

Aygun B, Padmanabhan S, Paley C, Chandrasekaran V.

Transfusion. 2002 Jan;42(1):37-43. Review.

PMID:
11896310
19.

Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura.

Scaradavou A, Bussel JB.

Semin Hematol. 1998 Jan;35(1 Suppl 1):52-7. Review.

PMID:
9523749
20.

Supplemental Content

Support Center